Tests dostarlimab before and after surgery for certain colon cancers
Tests dostarlimab with surgery in adults with resectable colon cancer.
Plain-language title generated from the registry record
Registry title: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Key facts
- Where
- Barretos, Belém, Campo Grande, Lages, Natal, Porto Alegre, Salvador, São José do Rio Preto, São Paulo, Teresina, and Vitória, BrazilSee the 11 sites
- Phase
- Phase 3
Where in Brazil
- BarretosBarretos, BrazilTaking people
- BelémBelém, BrazilTaking people
- Campo GrandeCampo Grande, BrazilTaking people
- LagesLages, BrazilTaking people
- NatalNatal, BrazilTaking people
- Porto AlegrePorto Alegre, BrazilTaking people
- SalvadorSalvador, BrazilTaking people
- São José do Rio PretoSão José do Rio Preto, BrazilTaking people
- São PauloSão Paulo, BrazilTaking people
- TeresinaTeresina, BrazilTaking people
- VitóriaVitória, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GlaxoSmithKline
- Trial code
- NCT05855200EU 2023-503265-27-00
- Record updated
- 23 January 2026
- Original description
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.Read full original descriptionShow less
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Inclusion: Has untreated pathologically confirmed colon adenocarcinoma; Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III; Has radiologically evaluable disease; Has a tumor demonstrating the presence of either dMMR status or MSI-H.
Exclusion: Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer; Has a tumor that, in the investigator's judgment is causing symptomatic bowel obstruction or otherwise requires urgent/emergent surgery at the time of screening. Participants with a history of colonic obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning ileostomy or colostomy). Patients with a history of colonic obstruction in the context of current colon cancer diagnosis and treated with colonic stents are not eligible; Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to randomization; Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention; Has distant metastatic disease; Has any history of interstitial lung disease or pneumonitis and/or history of radiation induced enteritis; Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice; Has a history of allogenic stem cell transplantation or organ transplantation; Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of FOLFOX or CAPEOX; Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study.